Expertise in
29
conditions

Dr. Tracy W. Dobbs

Oncology
Sweetwater Hospital
304 Church St, 
Sweetwater, TN 
Accepting New Patients
Offers Telehealth
Expertise in
29
conditions
Sweetwater Hospital
304 Church St, 
Sweetwater, TN 

Overview

Tracy Dobbs is an Oncologist practicing medicine in Sweetwater, Tennessee.

Dr. Dobbs is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Hereditary Retinoblastoma, Retinoblastoma, and Paget Disease of the Breast.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 4 clinical trials. Dr. Dobbs is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in TN

Hospital Affiliations

Fort Sanders Regional Medical Center
Physicians Regional Medical Center
Tennova Healthcare-Jefferson Memorial Hospital
Morristown Hamblen Hospital Association
Sweetwater Hospital Association

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Sweetwater Hospital
304 Church St, Sweetwater, TN 37874

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Terminated
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

2 Total Publications

AdvanTIG-204: A Phase 2, Randomized, Open-Label Study of Ociperlimab Plus Tislelizumab and Concurrent Chemoradiotherapy Versus Tislelizumab and Concurrent Chemotherapy Versus Concurrent Chemoradiotherapy in First-Line Limited-Stage SCLC.
AdvanTIG-204: A Phase 2, Randomized, Open-Label Study of Ociperlimab Plus Tislelizumab and Concurrent Chemoradiotherapy Versus Tislelizumab and Concurrent Chemotherapy Versus Concurrent Chemoradiotherapy in First-Line Limited-Stage SCLC.
Journal: JTO clinical and research reports
Published: March 05, 2025
Similar Doctors
Expertise in
26
conditions
Dr. Haydar A. Frangoul
Hematology | Oncology
Expertise in
26
conditions
Dr. Haydar A. Frangoul
Hematology | Oncology
Referral may be required

TriStar Medical Group Children's Specialists - West Clinch Ave

2018 Clinch Ave, 
Knoxville, TN 
 (38.4 miles away)
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Haydar Frangoul is a Hematologist and an Oncologist practicing medicine in Knoxville, Tennessee. Dr. Frangoul is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Beta Thalassemia, Congenital Hemolytic Anemia, Hemoglobinopathy, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Frangoul is currently accepting new patients.

Expertise in
60
conditions
Expertise in
60
conditions
Referral may be required

Tennessee Oncology

605 Glenwood Dr Ste 200, 
Chattanooga, TN 
 (60.4 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Davey Daniel is an Oncologist practicing medicine in Chattanooga, Tennessee. Dr. Daniel is highly rated in 60 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Non-Small Cell Lung Cancer (NSCLC), and Renal Cell Carcinoma (RCC). Dr. Daniel is currently accepting new patients.

Expertise in
68
conditions
Expertise in
68
conditions
Referral may be required

Tennessee Cancer Specialists PLLC

9957 Sherrill Blvd, 
Knoxville, TN 
 (29.1 miles away)
865-693-2255
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Ibach is an Oncologist practicing medicine in Knoxville, Tennessee. Dr. Ibach is highly rated in 68 conditions, according to our data. His clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Breast Cancer, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Ibach is currently accepting new patients.

Frequently Asked Questions about Dr. Tracy W. Dobbs

How do I make an appointment with Dr. Tracy W. Dobbs?

You can book an appointment with Dr. Tracy W. Dobbs by calling their office at 865-213-8200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tracy W. Dobbs a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tracy W. Dobbs is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tracy W. Dobbs specialize in?

While Dr. Tracy W. Dobbs is a Oncology, they have specific expertise in Breast Cancer, Hereditary Retinoblastoma, and Retinoblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Tracy W. Dobbs participate in research or clinical trials?

Yes. Dr. Tracy W. Dobbs has published 2 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Tracy W. Dobbs's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Tracy W. Dobbs accept my insurance?

Dr. Tracy W. Dobbs accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 865-213-8200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dobbs's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 20 Advanced Conditions
    View All 89 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile